GLP-1 drugs shifting food demand
Surging use of GLP-1 anti-obesity drugs is beginning to change how consumers shop and eat, with reports saying about one in eight U.S. adults now take these treatments and food makers seeing rising demand for smaller, more nutritious portions. Analysts highlight potential shifts toward satiety-focused formats and package-size innovation that could alter category dynamics for snacks and quick meals. ( )
Food and restaurant companies are redesigning products around smaller appetites as use of glucagon-like peptide-1, or GLP-1, drugs spreads across the United States. (kff.org) A November 14, 2025 KFF poll found 12% of U.S. adults said they were currently taking a GLP-1 drug such as Ozempic or Wegovy for weight loss, diabetes or another condition. Gallup separately found 12.4% of adults reported taking a GLP-1 medicine specifically for weight loss in mid-to-late 2025, up from 5.8% in February 2024. (kff.org; statista.com) These medicines slow digestion and increase the feeling of fullness, so users often eat less and skip between-meal snacking. CNBC reported on March 21 that restaurant chains and packaged-food companies are responding with more protein- and fiber-heavy items aimed at customers on the drugs. (cnbc.com) Food executives now describe that change as durable rather than temporary. Food Dive reported on February 25 that manufacturers are rolling out smaller portions and products with more protein and fiber as they plan for a “lasting influence” from GLP-1 use. (fooddive.com) That shift is showing up in packaging as much as in recipes. Reuters, in a February 18 report republished by GV Wire, said companies including PepsiCo and Coca-Cola were focusing on shorter ingredient lists and smaller pack sizes in 2026 as more consumers used appetite-suppressing drugs. (gvwire.com) Suppliers are also reworking what a “snack” is supposed to do. Food Business Gulf reported this week that manufacturers see rising demand for smaller portions that still feel indulgent but deliver more protein and fiber, as reduced appetite and less frequent eating change product design. (foodbusinessgulf.com) Restaurants are moving in the same direction. CNBC reported chains are adding meals and sides built around protein and fiber, while NBC News reported in February that some national chains were testing scaled-down portions at lower prices as smaller appetites become more common. (cnbc.com; nbcnews.com) Not everyone in the food business expects a broad collapse in demand. ING economists, cited last week by FoodIngredientsFirst, estimated GLP-1 adoption would trim food demand only 0.25% in 2026, while putting heavier pressure on categories such as snacks and alcohol than on the grocery aisle as a whole. (foodingredientsfirst.com) Brands are also testing labels aimed directly at drug users, but that market is still loosely defined. The Associated Press reported in February that “GLP-1 Friendly” labels are appearing on supermarket meals and snacks even though the U.S. Food and Drug Administration does not regulate that phrase. (ap.org) The immediate result is not one new diet but a new set of portion rules: less volume, more satiety, and more pressure on food companies to make smaller servings feel worth the price. (fooddive.com; foodbusinessgulf.com)
